Why this grouping
Grouped as a mechanistic lysosomal-storage subgroup: members conform to the lysosomal_substrate_accumulation module but are distinguished from the mucopolysaccharidoses by failure of lysosomal hydrolase targeting/trafficking or endolysosomal ion-channel function rather than deficiency of one GAG-catabolic enzyme. They are kept as separate Disease entries because GNPTAB loss causes severe I-cell disease, GNPTG loss causes the attenuated mucolipidosis III gamma phenotype, and MCOLN1 loss causes mucolipidosis IV with prominent neurodevelopmental and ocular disease.
Membership criteria
NECESSARY (member ⇒ criteria)
A member is a lysosomal storage disorder that conforms to the lysosomal substrate accumulation module and perturbs lysosomal hydrolase targeting, lysosomal transport, or autophagic-endolysosomal membrane function.
- AND
- CONFORMS TO MODULE
module: lysosomal_substrate_accumulation · Lysosomal Substrate Accumulation
Conforms to the lysosomal substrate accumulation module.
- OR
Perturbs hydrolase targeting, lysosomal transport, or autophagic endolysosomal membrane function.
- HAS BIOLOGICAL PROCESS
protein targeting to lysosome GO:0006622
Defective protein targeting to lysosome.
- HAS BIOLOGICAL PROCESS
lysosomal transport GO:0007041
Abnormal lysosomal transport.
- HAS BIOLOGICAL PROCESS
autophagy GO:0006914
Abnormal autophagy.
- HAS BIOLOGICAL PROCESS
protein targeting to lysosome GO:0006622
- CONFORMS TO MODULE
module: lysosomal_substrate_accumulation · Lysosomal Substrate Accumulation
Coverage and gaps
4 rows
Exact MONDO scope not assessed
4 listed with MONDO ID
No exact MONDO mapping is declared, so MONDO descendant gaps are not inferred for this grouping.
| Status | DisMech entry | MONDO concept | In DisMech | Has MONDO ID | In grouping MONDO | Member state | Conditions satisfied | C1.1 Conforms to the lysosomal substrate accumulation module. | C1.2 Defective protein targeting to lysosome. GO:0006622 | C1.3 Abnormal lysosomal transport. GO:0007041 | C1.4 Abnormal autophagy. GO:0006914 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| listed with MONDO ID |
GNPTG-Mucolipidosis
DISEASE
Differentiating mechanismGNPTG gamma-subunit deficiency attenuates GlcNAc-1-phosphotransferase function, producing a later-onset mucolipidosis III gamma phenotype with skeletal dysplasia, joint limitation, pain, and cardiac valve disease.
GNPTG hgnc:23026
|
GNPTG-mucolipidosis
MONDO:0009652
|
yes | yes | not assessed | listed | satisfied | SATISFIED | SATISFIED | SATISFIED | NOT SATISFIED |
| listed with MONDO ID |
Mucolipidosis Type II
DISEASE
Differentiating mechanismSevere GNPTAB-associated loss of GlcNAc-1-phosphotransferase abolishes mannose-6-phosphate tagging of soluble lysosomal hydrolases, causing missorting, hypersecretion, and multisubstrate lysosomal storage.
GNPTAB hgnc:29670
|
mucolipidosis type II
MONDO:0009650
|
yes | yes | not assessed | listed | satisfied | SATISFIED | SATISFIED | SATISFIED | NOT SATISFIED |
| listed with MONDO ID |
Mucolipidosis Type III Alpha/Beta
DISEASE
Differentiating mechanismAttenuated GNPTAB variants retain residual GlcNAc-1-phosphotransferase activity, so the same alpha/beta-subunit gene that causes mucolipidosis II instead produces a slowly progressive, later-onset disorder of skeletal dysplasia, joint stiffness and pain, cardiac valve disease, and only mild CNS involvement — the allelic-severity counterpart of ML II and the alpha/beta-subunit counterpart of GNPTG-mucolipidosis (ML III gamma).
GNPTAB hgnc:29670
|
mucolipidosis type III, alpha/beta
MONDO:0018931
|
yes | yes | not assessed | listed | satisfied | SATISFIED | SATISFIED | SATISFIED | NOT SATISFIED |
| listed with MONDO ID |
Mucolipidosis Type IV
DISEASE
Differentiating mechanismMCOLN1/TRPML1 loss disrupts endolysosomal calcium signaling, autophagy, and membrane trafficking, producing a neurodevelopmental and ocular mucolipidosis rather than a hydrolase-targeting defect.
MCOLN1 hgnc:13356
|
mucolipidosis type IV
MONDO:0009653
|
yes | yes | not assessed | listed | satisfied | SATISFIED | NOT SATISFIED | NOT SATISFIED | SATISFIED |
Source
View YAML on GitHubRaw YAML
name: Mucolipidoses
display_name: Mucolipidoses
creation_date: "2026-06-18T00:00:00Z"
description: >-
The mucolipidoses are lysosomal storage disorders that combine
mucopolysaccharide-like and lipid-storage features, but arise from lysosomal
hydrolase trafficking, targeting, or endolysosomal membrane-transport defects
rather than a single GAG-degrading enzyme deficiency. The current DisMech
grouping spans GNPTAB/GNPTG GlcNAc-1-phosphotransferase defects and
MCOLN1/TRPML1 channel dysfunction.
grouping_basis:
- SHARED_MECHANISM
- SHARED_PATHWAY
grouping_rationale: >-
Grouped as a mechanistic lysosomal-storage subgroup: members conform to the
lysosomal_substrate_accumulation module but are distinguished from the
mucopolysaccharidoses by failure of lysosomal hydrolase targeting/trafficking
or endolysosomal ion-channel function rather than deficiency of one
GAG-catabolic enzyme. They are kept as separate Disease entries because
GNPTAB loss causes severe I-cell disease, GNPTG loss causes the attenuated
mucolipidosis III gamma phenotype, and MCOLN1 loss causes mucolipidosis IV
with prominent neurodevelopmental and ocular disease.
membership_criteria:
- description: >-
A member is a lysosomal storage disorder that conforms to the lysosomal
substrate accumulation module and perturbs lysosomal hydrolase targeting,
lysosomal transport, or autophagic-endolysosomal membrane function.
criteria_semantics: NECESSARY
logic:
operator: AND
operands:
- criterion_predicate: CONFORMS_TO_MODULE
module: lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation
description: >-
Conforms to the lysosomal substrate accumulation module.
- operator: OR
description: >-
Perturbs hydrolase targeting, lysosomal transport, or autophagic
endolysosomal membrane function.
operands:
- criterion_predicate: HAS_BIOLOGICAL_PROCESS
description: Defective protein targeting to lysosome.
biological_processes:
- preferred_term: protein targeting to lysosome
term:
id: GO:0006622
label: protein targeting to lysosome
modifier: DECREASED
- criterion_predicate: HAS_BIOLOGICAL_PROCESS
description: Abnormal lysosomal transport.
biological_processes:
- preferred_term: lysosomal transport
term:
id: GO:0007041
label: lysosomal transport
modifier: ABNORMAL
- criterion_predicate: HAS_BIOLOGICAL_PROCESS
description: Abnormal autophagy.
biological_processes:
- preferred_term: autophagy
term:
id: GO:0006914
label: autophagy
modifier: ABNORMAL
members:
- member: Mucolipidosis Type II
member_type: DISEASE
display_name: Mucolipidosis type II (I-cell disease)
differentiating_mechanisms:
- description: >-
Severe GNPTAB-associated loss of GlcNAc-1-phosphotransferase abolishes
mannose-6-phosphate tagging of soluble lysosomal hydrolases, causing
missorting, hypersecretion, and multisubstrate lysosomal storage.
gene:
preferred_term: GNPTAB
term:
id: hgnc:29670
label: GNPTAB
- member: GNPTG-Mucolipidosis
member_type: DISEASE
display_name: Mucolipidosis III gamma
differentiating_mechanisms:
- description: >-
GNPTG gamma-subunit deficiency attenuates GlcNAc-1-phosphotransferase
function, producing a later-onset mucolipidosis III gamma phenotype with
skeletal dysplasia, joint limitation, pain, and cardiac valve disease.
gene:
preferred_term: GNPTG
term:
id: hgnc:23026
label: GNPTG
- member: Mucolipidosis Type IV
member_type: DISEASE
display_name: Mucolipidosis type IV
differentiating_mechanisms:
- description: >-
MCOLN1/TRPML1 loss disrupts endolysosomal calcium signaling, autophagy,
and membrane trafficking, producing a neurodevelopmental and ocular
mucolipidosis rather than a hydrolase-targeting defect.
gene:
preferred_term: MCOLN1
term:
id: hgnc:13356
label: MCOLN1
- member: Mucolipidosis Type III Alpha/Beta
member_type: DISEASE
display_name: Mucolipidosis III alpha/beta (pseudo-Hurler polydystrophy)
differentiating_mechanisms:
- description: >-
Attenuated GNPTAB variants retain residual GlcNAc-1-phosphotransferase
activity, so the same alpha/beta-subunit gene that causes mucolipidosis II
instead produces a slowly progressive, later-onset disorder of skeletal
dysplasia, joint stiffness and pain, cardiac valve disease, and only mild
CNS involvement — the allelic-severity counterpart of ML II and the
alpha/beta-subunit counterpart of GNPTG-mucolipidosis (ML III gamma).
gene:
preferred_term: GNPTAB
term:
id: hgnc:29670
label: GNPTAB
notes: >-
Nested LSD subgroup. It should be represented as a GROUPING member of
Lysosomal Storage Disorders rather than mixing its individual members at the
parent LSD level.